... Immunotherapy and chemoimmunotherapy for patients with previously untreated advanced or metastatic esophageal adenocarcinoma or gastroesophageal junction cancer Immunotherapy for patients who ...

... and chemoimmunotherapy for patients with previously untreated, unresectable, advanced or metastatic esophageal adenocarcinoma or gastroesophageal junction cancer. Immunotherapy for patients with ...

... folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann ...

... series of individuals with recurrent or refractory, locally advanced or metastatic, CLDN18.2‐positive gastric, gastro‐esophageal junction, or esophageal adenocarcinoma. Of the 54 individuals enrolled in this trial, ...

... 90% of all esophageal tumors. The incidence of esophageal adenocarcinomas has risen considerably for the past two decades, ... human papillomavirus),[ 5 ] the risk factors associated with esophageal adenocarcinoma are less defined. The most important epidemiological difference ...

... esophagus is associated with an increased risk of esophageal adenocarcinoma. Other factors that may explain the increased risk ... A meta-analysis of 1,128 individuals with esophageal adenocarcinoma from five case-control studies reported statistically significant ...

... cancer stage I endometrial stromal sarcoma stage I esophageal adenocarcinoma stage I esophageal squamous cell carcinoma stage I ... cancer stage II endometrial stromal sarcoma stage II esophageal adenocarcinoma stage II esophageal squamous cell carcinoma stage II ...

... known as Barrett’s esophagus, as well as esophageal adenocarcinoma. These GERD complications can result in hospitalizations for ... an esophageal disorder. From 1998 to 2005, dysphagia, esophageal adenocarcinoma, and esophagitis were the fastest growing esophageal disorders ...